Invivyd (IVVD) Study result summary
Event summary combining transcript, slides, and related documents.
Study result summary
3 Nov, 2026Study design
Phase 3 LIBERTY randomized 210 healthy adults aged 18–49 in a double-blind, active-controlled study of VYD2311, an mRNA vaccine, or both; safety assessments covered 6 and 56 days.
LIBERTY evaluated safety, tolerability, and immunologic interference; it had no placebo arm and was not designed to establish efficacy.
Safety and tolerability
VYD2311 met LIBERTY’s primary and secondary endpoints, showing superior safety and tolerability to the mRNA vaccine.
At 6 days, any TEAE, injection-site reaction, or hypersensitivity occurred in 56.5% of VYD2311 recipients versus 91.4% with vaccine (P<0.0001); systemic adverse events occurred in 44.1% versus 68.1% (P=0.008).
At 56 days, any TEAE, injection-site reaction, or hypersensitivity occurred in 60.9% of VYD2311 recipients versus 83.1% with vaccine (P<0.0001).
No VYD2311-related adverse events exceeded Grade 2, and no hypersensitivity, anaphylaxis, myocarditis, or pericarditis occurred in any arm.
Combination dosing was associated with fewer systemic events than vaccine alone, suggesting improved vaccine tolerability.
Immunogenicity
Co-administration increased total neutralizing titers by ~2.5x versus vaccine alone, with no evidence of immunologic interference.
After VYD2311 was selectively removed from samples, vaccine-induced neutralization titers matched those in the vaccine-only arm.
Monotherapy immunogenicity findings were preliminary and underpowered; further review alongside DECLARATION data was anticipated.
Latest events from Invivyd
- PEMGARDA revenue grew 18%, while losses and financing needs rose as VYD2311 advanced.IVVD
Q3 2026 - VYD2311 aims to transform infectious disease prevention with scalable, flexible antibody protection.IVVD
H.C. Wainwright 28th Annual Global Investment Conference - Q2 2026 revenue grew 21% but net loss widened, with future revenue at risk from PEMGARDA EUA expiry.IVVD
Q2 2026 - VYD2311 advances toward late-stage COVID-19 prevention, with broad pipeline and market ambitions.IVVD
H.C. Wainwright “HCW @ Home” Series - Antibody-based prevention aims to surpass vaccines in protection, safety, and patient preference.IVVD
Jefferies Global Healthcare Conference 2026 - Directors were elected and the auditor ratified, with no additional proposals or questions.IVVD
AGM 2026 - Q3 revenue up 41% YoY to $13.1M, net loss narrowed, and pivotal VYD2311 trials set for year-end.IVVD
Q3 2025 - VYD2311 aims for durable, safe COVID protection with strong efficacy in pivotal prevention trials.IVVD
Study Update - Q2 PEMGARDA launch drove $2.3M revenue, but cash runway is under one year.IVVD
Q2 2024